Publication
A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts
Downloadable Content
- Persistent URL
- Last modified
- 02/25/2025
- Type of Material
- Authors
- Language
- English
- Date
- 2015-11-01
- Publisher
- Elsevier
- Publication Version
- Copyright Statement
- © 2015 AGA Institute.
- License
- Final Published Version (URL)
- Title of Journal or Parent Work
- ISSN
- 0016-5085
- Volume
- 149
- Issue
- 6
- Start Page
- 1501
- End Page
- 1510
- Grant/Funding Information
- Supported by The Lustgarten Foundation for Pancreatic Cancer Research, The Sol Goldman Center for Pancreatic Cancer Research, The Virginia and D.K. Ludwig Fund for Cancer Research, Susan Wojcicki and Dennis Troper, The Michael Rolfe Foundation, National Institutes of Health grant P50 CA62924, Associazione Italiana Ricerca Cancro (12182) Italian Ministry of Research (FIRB RBAP10AHJB) and Health (FIMP J33G13000210001).
- Supplemental Material (URL)
- Abstract
- Background & Aims: The management of pancreatic cysts poses challenges to both patients and their physicians. We investigated whether a combination of molecular markers and clinical information could improve the classification of pancreatic cysts and management of patients. Methods: We performed a multi-center, retrospective study of 130 patients with resected pancreatic cystic neoplasms (12 serous cystadenomas, 10 solid-pseudopapillary neoplasms, 12 mucinous cystic neoplasms, and 96 intraductal papillary mucinous neoplasms). Cyst fluid was analyzed to identify subtle mutations in genes known to be mutated in pancreatic cysts (BRAF, CDKN2A, CTNNB1, GNAS, KRAS, NRAS, PIK3CA, RNF43, SMAD4, TP53 and VHL); to identify loss of heterozygozity at CDKN2A, RNF43, SMAD4, TP53, and VHL tumor suppressor loci; and to identify aneuploidy. The analyses were performed using specialized technologies for implementing and interpreting massively parallel sequencing data acquisition. An algorithm was used to select markers that could classify cyst type and grade. The accuracy of the molecular markers were compared with that of clinical markers, and a combination of molecular and clinical markers. Results: We identified molecular markers and clinical features that classified cyst type with 90%–100% sensitivity and 92%–98% specificity. The molecular marker panel correctly identified 67 of the 74 patients who did not require surgery, and could therefore reduce the number of unnecessary operations by 91%. Conclusions: We identified a panel of molecular markers and clinical features that show promise for the accurate classification of cystic neoplasms of the pancreas and identification of cysts that require surgery.
- Author Notes
- Keywords
- Research Categories
- Health Sciences, Medicine and Surgery
- Health Sciences, Pathology
Tools
- Download Item
- Contact Us
-
Citation Management Tools
Relations
- In Collection:
Items
| Thumbnail | Title | File Description | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|---|
|
|
Publication File - rthnk.pdf | Primary Content | 2025-02-21 | Public | Download |